On May 19, 2025, Chuangxin International Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "Chuangxin International") officially announced the completion of nearly RMB 100 million in Series B financing. This round of financing was jointly led by Guangdong Science and Technology Fund and Zhongshan Hao Chuang Fund under Donghai Investment Control, helping Chuangxin International accelerate the research and development transformation of organoid technology and global commercial layout, injecting strong innovation momentum into the biomedical field.

As a leading enterprise in the whole industry chain of organoids, Chuangxin International has built an integrated ecological platform covering the whole life cycle of organoids based on its core technology system of independent innovation. The company focuses on three strategic directions: precision medicine, new drug research and development, and intelligent manufacturing. It focuses on the large-scale application of organoid tumor treatment, regenerative medicine, and synthetic biology, breaks through the key bottlenecks of the industry, and promotes the leapfrog development of the organoid industry towards intelligence, standardization, and industrialization. Relying on the world's leading technology platform, multi-dimensional data intelligence system, and deep clinical resource collaboration, Chuangxin International continues to accelerate the global transformation and implementation of technological achievements, provide systematic support for innovative breakthroughs in the field of life sciences, and lead the industry from technology exploration to a new stage of industrial scale application.

The global biomedical paradigm shift has ushered in a window of explosive growth for the organoid industry

In April 2025, the US FDA issued a new bill that explicitly proposed to gradually phase out animal experimental models and recommended the use of human cell models including organoids, marking that the global life science research paradigm is accelerating its shift to a new model system that is "closer to the real human body". Organoids, as three-dimensional in vitro models that highly simulate the structure and function of human organs, have become a key tool for precision medicine and innovative drug research and development.

As a global pioneer in organoid technology, Chuangxin International is redefining the core path of life science research and development through underlying technology innovation and full-chain ecological reconstruction, providing breakthrough technological support for precision medicine, innovative drug development, and complex disease research.

Dr. Huang Min, Chairman and CEO of Innovent Biologics, said: "We would like to thank Guangdong Science and Technology Fund, Donghai Investment Holding and other investors for their high recognition and strategic support. Innovent Biologics will take this round of financing as an opportunity to build a technology ecosystem covering the entire life cycle of organoids with the three-dimensional drive of 'technology platform + data intelligence + industrial application', continue to increase core technology research and development and product innovation, form a product matrix in key tracks such as organoid intelligent devices and chips, data intelligence systems, promote technological breakthroughs and industrial upgrading, and strive to become a global leader in the organoid industry."

Investor’s view: optimistic about technology moat and commercialization path

Guangdong Science and Technology Fund said: "Innovative Core International has leading organoid technology and industrialization platform. Its technological achievements have great application value in cutting-edge fields such as precision medicine and new drug research and development, which is in line with our investment philosophy of focusing on the core track of science and technology. We believe that Innovative Core International will occupy a key position in the industry transformation.

Donghai Investment Holdings pointed out: As a flagship platform of Shenzhen Investment Holdings focusing on early and mid-stage scientific and technological enterprises, we highly recognize the technical depth and growth potential of Chuangxin International. This investment is not only an important part of our strategic layout in the field of biomedicine, but will also promote the high-quality development of the biomedicine industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area.

Reshaping the future of the industry with hard-core technology

This round of B financing is not only a deep recognition of the global capital market for the forward-looking technology and commercial value of Chuangxin International, but also marks a new era of large-scale and industrialized development of organoid technology. Its strategic layout focuses on global cutting-edge fields, and accelerates the widespread application of organoid technology in global pharmaceutical research and development through cross-regional collaboration and multi-dimensional resource integration. This process will not only reconstruct the global value chain of the biopharmaceutical industry, but also face the challenges of human health with scientific innovation, promote precision medicine to a new stage with higher efficiency and wider coverage, and inject lasting momentum into the progress of global life sciences.

https://news.yaozh.com/archive/45478.html